Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439880 · ClinicalTrials.gov registry record · Phase 2
Open Label Study of Long Term Evaluation Against LDL-C Trial
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,324
- Enrollment target
NCT01439880 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 1,324 participants.
The verdict
NCT01439880, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,324 participants
- Enrollment target
Study Summary
The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.
Interventions
- OTHER Standard of care
- BIOLOGICAL Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,324 participants |
| Start Date | 2011-10-07 |
| Est. Completion | 2018-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439880
The ClinicalTrials.gov registry entry for NCT01439880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT01439880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01439880 about?
NCT01439880 is a clinical study titled "Open Label Study of Long Term Evaluation Against LDL-C Trial". The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.
What is the current status of trial NCT01439880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,324 participants. The study started on 2011-10-07. Estimated completion is 2018-06-20.
What interventions are being tested in trial NCT01439880?
The interventions under investigation include: Standard of care (OTHER), Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01439880?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.